LinkedIn Profile

Access GEn1E Lifesciences historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:gen1elifesci 18860019 Jun 16th, 2024 12:00AM GEn1E Lifesciences Inc. 675 15.00 Open Jun 16th, 2024 07:15AM Jun 16th, 2024 06:34PM GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA. Open ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery Open El Camino Real Palo Alto California US GEn1E Lifesciences
private:gen1elifesci 18860019 Jun 15th, 2024 12:00AM GEn1E Lifesciences Inc. 675 15.00 Open Jun 15th, 2024 06:18AM Jun 15th, 2024 11:58PM GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA. Open ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery Open El Camino Real Palo Alto California US GEn1E Lifesciences
private:gen1elifesci 18860019 Jun 14th, 2024 12:00AM GEn1E Lifesciences Inc. 674 15.00 Open Jun 14th, 2024 02:33AM Jun 14th, 2024 12:01PM GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA. Open ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery Open El Camino Real Palo Alto California US GEn1E Lifesciences
private:gen1elifesci 18860019 Jun 13th, 2024 12:00AM GEn1E Lifesciences Inc. 674 15.00 Open Jun 13th, 2024 02:20AM Jun 13th, 2024 07:44PM GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA. Open ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery Open El Camino Real Palo Alto California US GEn1E Lifesciences
private:gen1elifesci 18860019 Jun 12th, 2024 12:00AM GEn1E Lifesciences Inc. 672 15.00 Open Jun 12th, 2024 02:32AM Jun 12th, 2024 12:37PM GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA. Open ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery Open El Camino Real Palo Alto California US GEn1E Lifesciences
private:gen1elifesci 18860019 Jun 11th, 2024 12:00AM GEn1E Lifesciences Inc. 673 15.00 Open Jun 11th, 2024 02:34AM Jun 11th, 2024 05:28PM GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA. Open ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery Open El Camino Real Palo Alto California US GEn1E Lifesciences
private:gen1elifesci 18860019 Jun 10th, 2024 12:00AM GEn1E Lifesciences Inc. 673 15.00 Open Jun 10th, 2024 02:37AM Jun 10th, 2024 01:09PM GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA. Open ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery Open El Camino Real Palo Alto California US GEn1E Lifesciences
private:gen1elifesci 18860019 Jun 9th, 2024 12:00AM GEn1E Lifesciences Inc. 673 15.00 Open Jun 9th, 2024 02:31AM Jun 9th, 2024 10:51PM GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA. Open ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery Open El Camino Real Palo Alto California US GEn1E Lifesciences
private:gen1elifesci 18860019 Jun 9th, 2024 12:00AM GEn1E Lifesciences Inc. 673 15.00 Open Jun 9th, 2024 02:31AM Jun 9th, 2024 02:31AM GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA. Open ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery Open El Camino Real Palo Alto California US GEn1E Lifesciences
private:gen1elifesci 18860019 Jun 8th, 2024 12:00AM GEn1E Lifesciences Inc. 673 15.00 Open Jun 8th, 2024 02:37AM Jun 8th, 2024 06:19PM GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA. Open ARDS, Inflammation, Rare Diseases, AI Platform, Clinical Stage, Immunomodulators, Y Combinator, Inflammatory Disease, Next-generation, Multi-target, Novel Drugs, Techbio, Machine Learning, Drug Development, and Drug Discovery Open El Camino Real Palo Alto California US GEn1E Lifesciences

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.